Heron Therapeutics, INC.: insider trades · United States · SEC (Form 4)

About Heron Therapeutics, INC.

Heron Therapeutics, Inc. /DE/ (ticker HRTX) is a U.S.-listed biopharmaceutical company trading on the NASDAQ market in the United States. The company is headquartered in Cary, North Carolina, and incorporated in Delaware. Heron describes itself as a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations that improve medical care, with a business model centered on hospital- and specialty-care products rather than broad primary-care franchises. Its corporate evolution reflects a transition from a drug-delivery technology developer to a commercial company with FDA-approved products. ([sec.gov](https://www.sec.gov/Archives/edgar/data/818033/000095017025028374/hrtx-20241231.htm?utm_source=openai)) Heron’s portfolio is concentrated in two main areas: acute care and oncology supportive care. In oncology support, CINVANTI is the company’s core legacy product, an aprepitant injectable emulsion used to help prevent chemotherapy-induced nausea and vomiting. SUSTOL, also aimed at CINV-related care, is being wound down, with the company stating that it expects the product to be phased out by the end of 2026. In acute care, ZYNRELEF is the key strategic asset: it is an extended-release local anesthetic used for postoperative pain management. APONVIE rounds out the platform as an injectable aprepitant formulation for the prevention of postoperative nausea and vomiting. ([ir.herontx.com](https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-first-quarter-2026-financial?utm_source=openai)) From a competitive standpoint, Heron operates in a focused niche where hospital adoption, clinical differentiation, reimbursement, and formulary access are critical. ZYNRELEF has gained commercial relevance in the U.S. thanks in part to reimbursement improvements, including a permanent product-specific J-code that went live in 2025, which should help billing clarity across care settings. APONVIE also benefits from alignment with standard PONV management pathways. That said, Heron remains a relatively small-cap specialty pharma company with a concentrated revenue base, so execution risk is materially linked to the commercial trajectory of a handful of products and to payer dynamics in the United States. ([ir.herontx.com](https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-q3-2025-financial-results-and?utm_source=openai)) Recent highlights include first-quarter 2026 results, where management reaffirmed full-year guidance and reiterated the company’s growth focus on ZYNRELEF and APONVIE while confirming the planned SUSTOL wind-down. In 2025, Heron also announced a settlement with Mylan related to CINVANTI and APONVIE patent litigation, which reduced an important legal overhang. Overall, HRTX is a NASDAQ-listed U.S. healthcare name with a specialty commercial profile, exposed to product uptake, reimbursement policy, and the company’s ability to sustain growth beyond its current product set. ([ir.herontx.com](https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-first-quarter-2026-financial?utm_source=openai))